Clinical trials: Contrast Agent
Contrast Medium
Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid
Iopromide (trade name is Ultravist) is on the market for more than 30 years and has been used more than 250 million times as X-ray contrast medium for patients.
- Trial name
- UVIA (NCT03622801)
- Testing
- Iopromide (Ultravist, BAY86-4877)
- Where
- Germany
- Volunteers
- 133,331 people
- Sponsor
- Bayer
Cataract, Lens Opacities
PMCF Study on Monofocal Toric IOL (PODEYE TORIC) in Asia
This is a single-center, prospective, open-label PMCF study whereby patients undergoing routine cataract surgery will have mono- or bilateral implantation of hydrophobic acrylic monofocal toric intraocular lens PODEYE TORIC…
- Conditions
- Cataract, Lens Opacities, Astigmatism
- Trial name
- PHY2102 (NCT04778501)
- Testing
- IOL implantation experimental
- Where
- Philippines
- Volunteers
- 45 people
- Sponsor
- Beaver-Visitec International, Inc.
Infertility
An Efficacy and Safety Study of Corifollitropin Alfa (MK-8962) in Contrast to Recombinant FSH for Use in Controlled Ovarian Stimulation of Indian Women (P07056, Also Known as MK-8962-029)
This study, conducted in India, will be recruiting women participants who are between the ages of 18 and 42, and who have an indication for controlled ovarian stimulation (COS), but have not yet undergone in-vitro fertilization…
- Trial name
- NCT01599494
- Testing
- MK-8962, recFSH, Ganirelix
- Sponsor
- Organon and Co
Cardiac Diseases
Safety and Efficacy Evaluation of NH002 as a Contrast Agent in Subjects Undergoing Cardiac Echocardiography
This is a Phase 3, prospective, open-label, multicenter study to assess the efficacy of NH002-enhanced echocardiography in subjects with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the left…
- Trial name
- NCT06815627
- Testing
- NH002 (Perflutren Lipid Microspheres) Injectable Suspension
- Where
- 6 sites in Taiwan
- Volunteers
- 150 people
- Sponsor
- Trust Bio-sonics, Inc.
Patient Participation
Safety and Performance of Optivantage Multi-use When Injecting Contrast Media for Contrast Enhanced CT Examination
The study is a prospective, single-arm observational multicenter clinical investigation. The primary objective is to confirm the safety and performance of the Optivantage® Injection System when injecting contrast media to…
- Trial name
- NCT05537779
- Testing
- CT examination
- Volunteers
- 100 people
- Sponsor
- Guerbet
Coronary Artery Disease, ST-segment Elevation Myocardial Infarction
Post-Marketing Safety Study in ST-Segment Elevation Myocardial Infarction (STEMI) Participants Undergoing Primary Percutaneous Coronary Intervention (PCI) Procedure With VISIPAQUE® as the Contrast Medium
The purpose of this study is to prospectively observe the incidence rate of acute kidney injury (AKI), major adverse renal and cardiovascular events (MARCE) in participants who were diagnosed with ST-segment elevation myocardial…
- Trial name
- NCT03671603
- Testing
- Iodixanol
- Where
- 36 sites in China, South Korea
- Volunteers
- 2,755 people
- Sponsor
- GE Healthcare
Fibrosis, Kidney Failure
Risk of Nephrogenic Systemic Fibrosis (NSF) in Patients With Moderate Renal Insufficiency After the Administration of Magnevist
Assess potential risk for NSF in subjects with renal impairment (moderate) post magnevist injection. Subjects will be screened within 48 hours of previously scheduled MRI, those meeting the enrollment criteria will be enrolled…
- Conditions
- Fibrosis, Kidney Failure, Renal Insufficiency
- Trial name
- NCT00744939
- Testing
- Gadopentetate dimeglumine (Magnevist, BAY86-4882)
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- Bayer
Intraoperative Ureter Injury
Open-label Study to Evaluate Nerindocianine as a Surgical Aid in Ureter Delineation During Minimally Invasive Surgery
Phase 2, multicenter, efficacy and safety study evaluating the use of nerindocianine for the delineation of abdominopelvic ureter anatomy via near infrared fluorescence imaging during minimally invasive lower abdominal surgery…
- Trial name
- NCT04636567
- Testing
- Nerindocianine for injection
- Where
- 2 sites in United States
- Sponsor
- Li-Cor, Inc.
Magnetic Resonance Imaging
Phase Ib, Administration the IOP Injection for MRI Contrast Agent in Healthy Subjects
The objective of the study is to assess the dose dependent changes in MRI signal intensity (SI) in liver after IOP Injection intravenous administration in healthy volunteers.
- Trial name
- NCT03399214
- Testing
- IOP Injection
- Where
- Taiwan
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- MegaPro Biomedical Co. Ltd.
Drug Safety
Comparing Patient Comfort and Safety Between Iodixanol and Iopamidol in Patients Undergoing Peripheral Arteriography
The purpose of this study is to evaluate and compare overall patient comfort profile between an Iso-osmolar contrast media (IOCM), iodixanol 320 mg I/mL, and a Low-osmolar contrast media (LOCM), iopamidol 370 mg I/mL in patients…
- Trial name
- NCT01475097
- Testing
- Iodixanol, Iopamidol
- Where
- United States
- Volunteers
- 255 people
- Sponsor
- GE Healthcare
Night Vision Complaints, Decrease in Night Vision
The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Disturbances
The objectives of this study are: To evaluate the efficacy of phentolamine mesylate 0.5% and 1.0% ophthalmic solution (Nyxol) in the treatment of night vision complaints, including reduced contrast sensitivity To evaluate the…
- Conditions
- Night Vision Complaints, Decrease in Night Vision, Disturbance; Vision, Loss
- Trial name
- NCT01703559
- Testing
- Phentolamine Mesylate Ophthalmic Solution 1.0%, Phentolamine Mesylate Ophthalmic Solution 0.5%
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Opus Genetics, Inc
Congestive Heart Failure, Chronic Obstructive Pulmonary Disease
Phase 1 Safety and Pharmacokinetic Study of AI-700 in Patients With Diminished DLCO and COPD and/or CHF
This study was conducted to evaluate the safety and pharmacokinetics of an echocardiographic contrast agent, AI-700, in patients with moderate to severe chronic obstructive pulmonary disease (COPD) and/or congestive heart failure…
- Trial name
- NCT00156780
- Testing
- AI-700
- Where
- United States
- Sponsor
- Acusphere
Malignant Solid Tumor, Lymphomas
Safety and Pharmacokinetic Study of RRx-001 in Cancer Subjects
The purpose of this study is to evaluate the safety and pharmacokinetic profile of RRx-001 for injection in subjects with advanced solid tumors or lymphomas for which there are no currently accepted curative therapies.
- Trial name
- DINAMIC (NCT01359982)
- Testing
- RRx-001
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- EpicentRx, Inc.
Chronic Kidney Disease
DyeVert™ Plus Contrast Reduction System Multicenter Observational Study
This is a prospective, single arm, multi-center, observational clinical study of the DyeVert Plus System. The DyeVert Plus System is an FDA-cleared device designed to reduce contrast media volume delivered during angiography and…
- Trial name
- NCT03715452
- Testing
- DyeVert Plus Contrast Reduction System
- Where
- 8 sites in United States
- Volunteers
- 114 people
- Sponsor
- Osprey Medical, Inc
Central Nervous System Indication, Pediatric Patients
Pharmacokinetics, Safety and Efficacy of P03277 in Pediatric Patients Undergoing Central Nervous System Contrast-enhanced MRI
This is a pharmacokinetics (PK), open-label, uncontrolled, multicenter phase II trial with age-staggered approach. The primary objective is to evaluate the PK profile of gadopiclenol in plasma following single IV injection of…
- Conditions
- Central Nervous System Indication, Pediatric Patients, Body Indication
- Trial name
- NCT03749252
- Testing
- P03277
- Where
- 16 sites in Bulgaria, Hungary and 3 more
- Volunteers
- 80 people
- Sponsor
- Guerbet
Cardiovascular Diseases, Microvascular Complications
Non-invasive Microvascular Assessment in Individuals at High Risk of Cardiovascular Disease From the SCAPIS2 Study
Microvascular dysfunction, particularly endothelial dysfunction, is increasingly recognized as a key mechanism underlying various cardiovascular diseases (CVD), including heart failure, ischemic heart disease, atherosclerosis…
- Trial name
- NCT07359768
- Where
- Sweden
- Volunteers
- 900 people
- Sponsor
- HJN Sverige AB/Neko Health